LifeMD’s (LFMD) Buy Rating Reiterated at HC Wainwright

LifeMD (NASDAQ:LFMD)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 26.32% from the company’s previous close.

Several other brokerages have also commented on LFMD. Cantor Fitzgerald boosted their price objective on LifeMD from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday. BTIG Research boosted their price target on shares of LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $11.60.

LifeMD Trading Up 2.2 %

Shares of LifeMD stock opened at $9.50 on Friday. The company’s 50-day moving average price is $10.21 and its 200-day moving average price is $8.09. The company has a market cap of $388.46 million, a price-to-earnings ratio of -13.57 and a beta of 1.38. LifeMD has a 12-month low of $1.66 and a 12-month high of $12.88. The company has a current ratio of 1.22, a quick ratio of 1.15 and a debt-to-equity ratio of 3.22.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. The firm had revenue of $44.86 million during the quarter, compared to the consensus estimate of $40.65 million. On average, equities analysts expect that LifeMD will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeMD

A number of hedge funds have recently made changes to their positions in LFMD. Blair William & Co. IL bought a new position in shares of LifeMD during the 1st quarter valued at $642,000. Russell Investments Group Ltd. grew its stake in shares of LifeMD by 251.0% during the first quarter. Russell Investments Group Ltd. now owns 64,927 shares of the company’s stock valued at $667,000 after buying an additional 46,428 shares during the last quarter. Thompson Davis & CO. Inc. lifted its stake in shares of LifeMD by 182.8% in the 1st quarter. Thompson Davis & CO. Inc. now owns 40,000 shares of the company’s stock valued at $411,000 after acquiring an additional 25,855 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of LifeMD in the 1st quarter valued at about $432,000. Finally, G2 Investment Partners Management LLC boosted its holdings in LifeMD by 23.9% during the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock valued at $5,704,000 after acquiring an additional 132,850 shares during the period. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.